【04/26更新】(株)ジーエヌアイグループ【2160】が大ピンチ…！？掲示板、Twitterの反応は！？

>
>
>>あなた
>
>>ここの古参のスクショ見たことないのかな？
>
>>信用買いが多いのは
>
>>その連中の影響もあるかも？
>
>>
>
>>そう思って相場見ています
>
>>NISAも実際に
>
>>安く持っていると思っています
>
>>
>
>>買いなおせば
>
>>現物
>
>>コスト上がるでしょ
>
>>・・・
>
>>簿価あげても
>
>>恩株投資家さんなら
>
>>単価維持優先さんもいるでしょ・・・
>
>>
>
>>信用組回転屋さんも個人の都合あると思います？
>
>>感想です
>
>
>
>
>
>
>
>



100円以下で買ったgni株を未だに保有していると言うコメに、単純に意味はないのではと思っただけです‼️
私のコメに深い意味はありません‼️

１１年も前からＧＮＩに目を付けれてて良いですね。
その位からの方のコメントで、ＧＮＩに出会って人生変わりましたって
見た事ありますけど、私も１０年後にそう言いたいです。笑

ただ、今の１０年前にＧＮＩに出会ってても、私は買えてる自信がないです。笑

今日の
大漁旗引き抜き前哨戦、大引けの攻防見て
買いやめたと言った人いますが？

買い戻し競争にしり込みしたのかな？
大口さんは露骨ですね
大引1分間でも25900株約定
買い約定が92％弱
売り約定が約8％強です

圧倒されたですね.
赤組さん ^^) _旦~~

プレミアム効果逃すなでしょうか？？
感想です

GNIに文句言いたい人がたくさんいるのは理解してます。

でも、GNIは順調です。

GNI株価の乱高下を作っているのは、我々投資家側です(個人投資家、機関投資家、裁定取引等のアルゴリズム)。

あなた
ここの古参のスクショ見たことないのかな？
信用買いが多いのは
その連中の影響もあるかも？

そう思って相場見ています
NISAも実際に
安く持っていると思っています

買いなおせば
現物
コスト上がるでしょ
・・・
簿価あげても
恩株投資家さんなら
単価維持優先さんもいるでしょ・・・

信用組回転屋さんも個人の都合あると思います？
感想です

明日は悪天候になるようですわ
体調には気をつけてください！

それに早く気付いたから、kabさんは早くにGNIに資金の多くをGNIに突っ込めた。

あたすは、GNI？遺伝子解析技術？
→なんかちょっと上がりそう❤️
思ってちょびっと買いました。

他に免疫生物や、デ・ウエスタンや他にも買ったような気はしますが、、、

今更後悔しても意味ないので、第2のGNIに投資してますよ。

いやいや

当時グニちゃんだけが
輝いて見えました

何よりルイさんの経歴見て
確信して全力買いしましたよ

ここは連中前のあと２日、強引な売りをいかにうまく拾うかでしょう。
連休明けに新株行使完了関連情報で急に動きだすと思います。＾＾

当時は1000株価2万5〜6千円で買えましたね。
3.11後はその半分くらいになった記憶あります。

当時キングオブ糞株だったGNIが、時価総額1000億円になったのは感慨深いです。
GNI以外もバーゲンセールでした(笑)

テスタ氏そーせいGNI全力して人生挽回

グニグイグイ

>>372
GNIでわろた

グニつよい

Magnitude 5.7 earthquake offshore Chile

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

Chinese President Xi: Instabilities And Uncertainties Of The World Have Significantly Increased - Boao Forum

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

気文2160助かりますか？お願いします

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf
https://www.axcelead-hd.com/

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

GNI↑

U.S. RECOGNIZES DEEP ECONOMIC AND COMMERCIAL TIES BETWEEN JAPAN AND CHINA AND RESPECTS SUGA'S DESIRE TO WALK A CAREFUL COURSE - OFFICIAL

グミは頑張ってるのグニと言ったら全く…

グミと間違えてグニ買ったけどこっちもこっちでひでぇ
バイオやんけ…

イメージワンはGNIを思い出す

重要な発表まで株価上げ続けて、発表でもって滝行

GNI　完全に終了

GNI　おわった

GNI↑

バブグニ悲惨やな
バブグミとバブチームもぱっとしないし、バブターツなんて出来高400株とかどうすんのよ
バブ旛くらいやん

RBA Financial Stability Review

- Banks could handle a significant economic deterioration

- Office vacancies in Sydney and Melbourne near a 20-year high

- BBG